迪瑞医疗(300396) - 2022 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2022 was CNY 226,514,694.52, an increase of 14.07% compared to CNY 198,572,194.45 in the same period last year[3] - Net profit attributable to shareholders was CNY 60,813,979.13, up 4.08% from CNY 58,429,472.14 year-on-year[3] - Total operating revenue for the first quarter was CNY 226,514,694.52, an increase of 14.1% compared to CNY 198,572,194.45 in the previous year[28] - The net profit for the first quarter was 60,813,599.46, an increase from 58,429,472.14 in the previous year, representing a growth of approximately 4.1%[34] - The total profit amounted to 67,159,336.82, compared to 66,538,342.17 in the same period last year, indicating a year-over-year increase of about 0.9%[34] - The basic and diluted earnings per share were both 0.2218, up from 0.2132 in the previous year, reflecting a growth of approximately 2.7%[34] - Operating profit for the quarter was 67,273,409.04, slightly higher than 66,638,884.70 from the previous year, showing an increase of about 1.0%[34] Cash Flow and Liquidity - Net cash flow from operating activities decreased by 263.85%, resulting in a net outflow of CNY 29,426,149.07 compared to a net inflow of CNY 17,958,783.92 in the previous year[3] - Cash flow from operating activities was negative at -29,426,149.07, a decline from a positive cash flow of 17,958,783.92 in the same quarter last year[38] - Cash and cash equivalents at the end of the reporting period amounted to RMB 501.36 million, an increase from RMB 460.70 million at the beginning of the year[18] - Cash and cash equivalents at the end of the period totaled 485,799,731.61, down from 748,490,191.17 at the end of the previous year[41] - The company reported a cash and cash equivalents balance of CNY 275,603.00, indicating liquidity management[21] - The company generated cash inflow from investment activities of 572,600,157.33, significantly higher than 59,300,000.00 in the previous year[38] - The company’s financial report indicates a significant increase in cash flow, reflecting strong liquidity management[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,359,733,681.74, a decrease of 0.67% from CNY 2,375,626,201.07 at the end of the previous year[3] - Total assets decreased to CNY 2,359,733,681.74 from CNY 2,375,626,201.07, a decline of 0.7%[27] - Total liabilities decreased to CNY 469,937,609.99 from CNY 499,277,247.97, a reduction of 5.9%[27] - Inventory increased to CNY 249,087,289.79 from CNY 237,300,858.83, reflecting a growth of 4.8%[21] - The company’s equity attributable to shareholders rose to CNY 1,889,790,810.07 from CNY 1,876,348,953.10, an increase of 0.7%[27] Shareholder Information and Repurchase - The total number of common shareholders at the end of the reporting period is 12,676, with the largest shareholder holding 28.01% of shares[12] - The company repurchased a total of 2,763,000 shares, accounting for 1.0015% of the total share capital, with a total payment of approximately RMB 48.04 million[17] - The company plans to use between RMB 50 million and RMB 100 million for share repurchase, with a maximum price of RMB 27.00 per share[17] - The largest shareholder, Shenzhen Huade Xinrun Equity Investment Enterprise, holds 77,288,400 shares, representing 28.01% of the total shares[12] - The company’s total number of shares repurchased as of now is 2,797,000, with a total payment of approximately RMB 48.60 million[17] - The highest transaction price for repurchased shares was RMB 19.09, while the lowest was RMB 15.76[17] Operational Performance and Future Outlook - The company aims to overcome operational challenges in Q2 2022 and maintain a good growth rate for the year despite the impact of the pandemic[7] - The company has partially resumed operations and is confident in making up for the first quarter shortfall through comprehensive production adjustments[7] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[26] Expenses - Total operating costs amounted to CNY 169,474,938.59, up 20.8% from CNY 140,288,213.40 in the same period last year[28] - Research and development expenses were CNY 20,677,466.87, slightly higher than CNY 20,115,688.19 in the previous year[28] - The company incurred a tax expense of 6,345,737.36, down from 8,108,870.03 in the previous year, representing a decrease of about 21.8%[34] Other Financial Metrics - The weighted average return on equity was 3.19%, down from 3.47% in the previous year[3] - The company reported a foreign exchange loss of -277,466.82, contrasting with a gain of 36,870.17 in the previous year[34] - The company reported a 116.79% increase in net cash flow from investing activities, totaling CNY 6,864,950.00, mainly due to the purchase of financial products[10] - The company experienced a 51.50% increase in prepayments, amounting to CNY 8,281,900.00, primarily due to increased raw material purchases[7] - Long-term receivables increased by 30.04%, reaching CNY 7,800,000.00, attributed to an increase in installment sales[7]